<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
  • Menu
  • crown-logo-symbol-1-400x551

Find it Quickly

Get Started

Select the option that best describes what you are looking for

  • Services
  • Models
  • Scientific Information

Search Here For Services

Click Here to Start Over

Search Here For Models

Click Here to Start Over

Search Here For Scientific Information

Click Here to Start Over

In Vitro

Boost oncology drug discovery with XenoBase®, featuring the largest cell line selection and exclusive 3D organoid models. Benefit from OrganoidXplore™ and OmniScreen™ for rapid, in-depth analysis.

Learn More

In Vivo

Enhance drug development with our validated in vivo models, in vitro/ex vivo assays, and in silico modeling. Tailored solutions to optimize your candidates.

Learn More

Tissue

Experience ISO-certified biobanking quality. Access top biospecimens from a global clinical network, annotated by experts for precise research.

Learn More

Biomarkers and Bioanalysis

Leverage our global labs and 150+ scientists for fast, tailored project execution. Benefit from our expertise, cutting-edge tech, and validated workflows for reliable data outcomes.

Learn More

Data Science and Bioinformatics

Harness your data and discover biomarkers with our top bioinformatics expertise. Maximize data value and gain critical insights to accelerate drug discovery and elevate projects.

Learn More

KRAS

Accelerate innovative cancer treatments with our advanced models and precise drug screening for KRAS mutations, efficiently turning insights into clinical breakthroughs.

Learn More

EGFR

Advance translational pharmacology with our diverse pre-clinical models, robust assays, and data science-driven biomarker analysis, multi-omics, and spatial biology.

Learn More

Drug Resistance

Our suite integrates preclinical solutions, bioanalytical read-outs, and multi-omics to uncover drug resistance markers and expedite discovery with our unique four-step strategy.

Learn More

Patient Tissue

Enhance treatments with our human tumor and mouse models, including xenografts and organoids, for accurate cancer biology representation.

Learn More

Bioinformatics

Apply the most appropriate in silico framework to your pharmacology data or historical datasets to elevate your study design and analysis, and to improve your chances of clinical success.

Learn More

Biomarker Analysis

Integrate advanced statistics into your drug development projects to gain significant biological insight into your therapeutic candidate, with our expert team of bioinformaticians.

Learn More

CRISPR/Cas9

Accelerate your discoveries with our reliable CRISPR solutions. Our global CRISPR licenses cover an integrated drug discovery platform for in vitro and in vivo efficacy studies.

Learn More

Genomics

Rely on our experienced genomics services to deliver high quality, interpretable results using highly sensitive PCR-based, real-time PCR, and NGS technologies and advanced data analytics.

Learn More

In Vitro High Content Imaging

Gain more insights into tumor growth and disease progression by leveraging our 2D and 3D fluorescence optical imaging.

Learn More

Mass Spectrometry-based Proteomics

Next-generation ion mobility mass spectrometry (MS)-based proteomics services available globally to help meet your study needs.

Learn More

Ex Vivo Patient Tissue

Gain better insight into the phenotypic response of your therapeutic candidate in organoids and ex vivo patient tissue.

Learn More

Spatial Multi-Omics Analysis

Certified CRO services with NanoString GeoMx Digital Spatial Profiling.

Learn More

Biomarker Discovery

De-risk your drug development with early identification of candidate biomarkers and utilize our biomarker discovery services to optimize clinical trial design.

Learn More

DMPK Services

Rapidly evaluate your molecule’s pharmaceutical and safety properties with our in vivo drug metabolism and pharmacokinetic (DMPK) services to select the most robust drug formulations.

Learn More

Efficacy Testing

Explore how the novel HuGEMM™ and HuCELL™ platforms can assess the efficacy of your molecule and accelerate your immuno-oncology drug discovery programs.

Learn More

Laboratory Services

Employ cutting-edge multi-omics methods to obtain accurate and comprehensive data for optimal data-based decisions.

Learn More

Pharmacology & Bioanalytical Services

Leverage our suite of structural biology services including, recombinant protein expression and protein crystallography, and target validation services including RNAi.

Learn More

Screens

Find the most appropriate screen to accelerate your drug development: discover in vivo screens with MuScreen™ and in vitro cell line screening with OmniScreen™.

Learn More

Toxicology

Carry out safety pharmacology studies as standalone assessments or embedded within our overall toxicological profiling to assess cardiovascular, metabolic and renal/urinary systems.

Learn More

Our Company

Global CRO in California, USA offering preclinical and translational oncology platforms with high-quality in vivo, in vitro, and ex vivo models.

Learn More

Our Purpose

Learn more about the impact we make through our scientific talent, high-quality standards, and innovation.

Learn More

Our Responsibility

We build a sustainable future by supporting employee growth, fostering leadership, and exceeding customer needs. Our values focus on innovation, social responsibility, and community well-being.

Learn More

Meet Our Leadership Team

We build a sustainable future by fostering leadership, employee growth, and exceeding customer needs with innovation and social responsibility.

Learn More

Scientific Advisory Board

Our Scientific Advisory Board of experts shapes our strategy and ensures top scientific standards in research and development.

Learn More

News & Events

Stay updated with Crown Bioscience's latest news, achievements, and announcements. Check our schedule for upcoming events and plan your visit.

Learn More

Career Opportunities

Join us for a fast-paced career addressing life science needs with innovative technologies. Thrive in a respectful, growth-focused environment.

Learn More

Scientific Publications

Access our latest scientific research and peer-reviewed articles. Discover cutting-edge findings and insights driving innovation and excellence in bioscience.

Learn More

Resources

Discover valuable insights and curated materials to support your R&D efforts. Explore the latest trends, innovations, and expertly curated content in bioscience.

Learn More

Blogs

Explore our blogs for the latest insights, research breakthroughs, and industry trends. Stay educated with expert perspectives and in-depth articles driving innovation in bioscience.

Learn More

  • Platforms
  • Target Solutions
  • Technologies
  • Service Types

New Analysis, Model ID, and Modeling Technologies at AACR 2019

New Analysis, Model ID, and Modeling Technologies at AACR 2019

New Analysis, Model ID, and Modeling Technologies at AACR 2019In Atlanta this week we’re presenting data on our new analysis platforms and preclinical technologies. This post recaps all the information on new CAR-T cell detection methods, an NGS-based SNP model identification array, data analysis platforms, and improvement on tumor growth mathematical model understanding.

Sensitive Detection and Quantification of CAR-T Cells in Treated Patients (AACR 2019, Poster 1443)

CAR-T cell therapy is a promising new personalized cancer treatment approach, using a patient’s own immune cells to fight cancer, and already FDA approved for treating certain types of NHL, DLBCL, and ALL.

Despite being clinically used, there are still some questions to answer around CAR-T cell therapy. Notably, CAR-T cells need to be effectively monitored and characterized after administration to fully understand treatment effects and underlying mechanisms.

We’ve developed a new platform to detect and characterize rare CAR-T cells in patients. Our new platform looks to overcome the limitations of existing technologies - flow cytometry which has a low sensitivity, and real-time PCR which can’t be used to identify and characterize individual CAR-T cells.

CAR-T Cell Detection and Monitoring using RareCyte Technology

Our platform uses the RareCyte system which is validated for CAR-T cell detection in this poster. Preliminary data shows that our new method has a high sensitivity, at least 3 orders of magnitude above flow cytometry. A good linear range of quantification was seen, and single CAR-T cells could be picked for further single cell characterization.

Overall, this CAR-T cell detection and monitoring method could provide a great new opportunity for the clinic, in monitoring patient treatment, and understanding treatment mechanisms. There’s also the potential for diagnostic development, to provide guidance on patient treatment and prognosis.

A NGS-Based SNP Array for the Identification of Human Xenograft Tumors, Mouse Homograft Tumors, Human and Mouse Cell Lines, and Organoids (AACR 2019, Poster 3418)

To ensure authenticity of the variety of preclinical tumor models used in oncology drug development, models need to be tracked and quality controlled. Our next AACR poster presents a novel platform which can QC both human and murine models, including xenograft and patient-derived xenograft (PDX) tumors, mouse homograft tumors, human and mouse cell lines, and organoids.

The new technology is built on Single Nucleotide Polymorphism (SNP) based assays, which have been used in recent years to replace STR profiling of human cell lines and models. SNP-based assays have improved accuracy, can be automated, use low sample amounts and degraded samples, and multiple SNPs can be assayed simultaneously by Next Generation Sequencing (NGS) technology.

Multiple Functions of NGS-Based SNP Array

The poster details validation of our NGS-based SNP array for different functions including authenticating PDX tumor models, detecting viral infection and mycoplasma contamination, and characterizing common immunodeficient mouse strains. Unique fingerprints of around 200 SNPs are generated for each tumor model through RNAseq or WES data, and the poster also details our wide range of models for which fingerprints have been generated.

Overall, this platform provides an efficient and robust method for authenticating tumor models which can be adopted for the quality assurance of banking and tracking tumor model collections.

Mathematical Modeling of Tumor Growth in Mouse Models (AACR 2019, Poster 4613)

Understanding the growth kinetics of tumor models is crucial for the accurate analysis of drug efficacy in preclinical cancer research. It’s known that different tumor models, like PDX, traditional xenografts, and syngeneics have different patterns of growth when being treated with vehicle or drugs.

Poster 4613 looked to answer the question of which mathematical models are best suited to describe tumor growth kinetics across different tumor models or for large numbers of tumors. While many models have been previously suggested for tumor growth kinetics, these two questions remain unanswered.

Evaluation of Eight Mathematical Models

We evaluated eight different mathematical models describing tumor growth kinetics, looking at vehicle and drug treatments using data from over 35,000 mice. The analysis covered conventional xenografts, PDX, and syngeneic models. Four goodness of fit criteria were used to assess the results.

Generally, we found that the mathematical models performed better for vehicle than drug groups, with mathematical model performance differing across the tumor models tested. The four goodness of fit criteria weren’t always consistent in assessing model performance, and overall we think further studies are needed to elucidate the applicability of the different mathematical models on individual datasets.

HuPharm: An Interactive Data Analysis Platform for Preclinical Studies (AACR 2019, Poster 5111)

With preclinical data helping decide which new agents move to clinical development, it’s important that preclinical studies are carefully planned, properly executed, and correctly analysed for statistical relevance.

We’ve developed a new web platform to help with in vivo pharmacology data analysis and interpretation. Based upon user inputs, our HuPharm platform automatically generates appropriate figures and tables which facilitates preclinical data analysis. The intuitive and interactive interface is designed to help researchers (including those with less statistical training) on data validation, exploratory data analysis, and statistical analysis.

Poster 5111 details the packages used to build this platform, what an average analysis pipeline looks like, and the types of figures, tables, and analysis a user can be expect to receive in their end statistical report.

We hope this platform, with standardized statistical analysis reports, can help ensure consistency and to boost preclinical study productivity.

Read More on AACR 2019

For more on our AACR19 presentations, read our posts on PDX, humanized, and syngeneic models and research.


Related Posts